NASDAQ:DTIL Precision BioSciences Q1 2026 Earnings Report $6.33 +0.07 (+1.12%) Closing price 10/1/2026 04:00 PM EasternExtended Trading$6.30 -0.03 (-0.47%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Precision BioSciences EPS ResultsActual EPS-$0.75Consensus EPS -$0.66Beat/MissMissed by -$0.10One Year Ago EPSN/APrecision BioSciences Revenue ResultsActual Revenue$10.84 millionExpected Revenue$4.05 millionBeat/MissBeat by +$6.79 millionYoY Revenue GrowthN/APrecision BioSciences Announcement DetailsQuarterQ1 2026Date5/5/2026TimeBefore Market OpensConference Call DateTuesday, May 5, 2026Conference Call Time9:30AM ETUpcoming EarningsPrecision BioSciences' Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Precision BioSciences Earnings HeadlinesPrecision BioSciences (NASDAQ:DTIL) Stock: Insider Geno Germano Purchases 2,609 SharesOctober 1 at 4:52 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE) and Precision BioSciences (DTIL)September 30 at 4:21 AM | theglobeandmail.comHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires. | Base Camp Trading (Ad)Precision Biosciences Inc.September 23, 2026 | barrons.comPrecision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD StudyAugust 24, 2026 | businesswire.comPrecision BioSciences: Promising HBV Editing EvidenceAugust 18, 2026 | seekingalpha.comSee More Precision BioSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email. Email Address About Precision BioSciencesPrecision BioSciences (NASDAQ:DTIL) is a biotechnology company developing gene-editing medicines for genetically driven diseases. The company’s platform, ARCUS, uses engineered homing endonucleases designed to make precise changes to DNA, including targeted gene insertion, deletion and correction. Precision’s pipeline has included in vivo gene-editing programs intended to address conditions such as Duchenne muscular dystrophy and chronic hepatitis B. The company has also developed allogeneic CAR T-cell candidates and has pursued collaborations and licensing arrangements to advance its gene-editing technology across therapeutic applications. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences conducts research and clinical development through operations and partnerships that support the development of genetic medicines in the United States and internationally.View Precision BioSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
